Ozempic has transformed public health and celebrity culture, and now it’s testing the boundaries of clean sport. WADA’s semaglutide review is a sign of how porous the elite sporting world has become.
As the Winter Olympics wind down, the World Anti-Doping Agency finds itself grappling with a distinctly modern problem: what to do when a blockbuster lifestyle drug becomes a potential performance enhancer.
GLP‑1 medications like Ozempic and Wegovy have reshaped public health, celebrity culture, and consumer behaviour. Now they’re testing the boundaries of elite sport; a space which has long imagined itself insulated from the trends shaping the rest of society.
WADA’s recently announced investigation into semaglutide, the active ingredient in these drugs, is a recognition the sporting world no longer sits apart from the pharmaceutical forces transforming everyday life. As Olivier Rabin, WADA’s senior director of Science and Medicine, told Sky News, the agency is observing a “change in paradigm” in how weight is managed in sport.
This shift is not happening in isolation and mirrors a broader cultural moment in which rapid, medically assisted weight loss has become normalised.
“We want to see whether we detect patterns of abuse of this drug or this class of substances in sport.”
Ollivier Rabi, Senior Director of Science and Medicine, WADA
The assumption that elite athletes are somehow immune to this trend is naïve. They live in the same world as everyone else, are exposed to the same medical innovations, the same pressures to optimise, and the same narratives about body management. And unlike the general population, athletes compete in environments where weight, body composition, and metabolic efficiency can directly influence performance.
That alone makes GLP‑1s a tempting proposition, even before you consider the commercial and social momentum behind them.
This is precisely why WADA appears uneasy. GLP‑1s occupy an uncomfortable middle ground: legitimate medical treatments on one hand, potential performance modifiers on the other. They don’t fit neatly into the traditional doping categories. They’re not anabolic steroids. They’re not stimulants. They’re not classic masking agents.
But they do alter appetite, energy balance, and body mass. These are factors which matter in endurance sports, weight‑category disciplines, aesthetic events, and even team sports where speed and load management are critical.
The challenge for regulators is that semaglutide’s rise is not driven by sport but by society. When a drug becomes this culturally dominant, the anti‑doping system is forced to confront a new reality: the line between “health” and “enhancement” is blurring, and athletes are caught in the middle.
The ‘spirit of sport’ clause (already one of WADA’s most subjective tools) becomes even harder to apply when the substance in question is prescribed to millions and marketed as a lifestyle reset.
There is also a practical dimension that if GLP‑1s remain legal in sport, governing bodies must accept that athlete physiology may shift in ways that are difficult to monitor. If they are banned, WADA must be confident in its ability to detect them reliably and fairly; and prepared for the inevitable debate about whether prohibition pushes use underground.
Neither path is straightforward.
But the bigger picture is this: semaglutide is unlikely to be the last mainstream drug with performance‑adjacent effects. Metabolic modifiers, cognitive enhancers, and recovery‑boosting therapies are already moving from clinical trials into consumer markets. GLP‑1s are simply the first to collide with elite sport at scale.
So how WADA responds now will set the tone for every similar debate that follows.
